19815-18-0Relevant articles and documents
Synthesis of novel arylaminoquinazolinylurea derivatives and their antiproliferative activities against bladder cancer cell line
Kim, Jung Hun,Kwak, Yeonui,Song, Chiman,Roh, Eun Joo,Oh, Chang-Hyun,Lee, So Ha,Sim, Taebo,Choi, Jung Hoon,Yoo, Kyung Ho
, p. 5082 - 5086 (2016)
A novel series of arylurea and arylamide derivatives 1a–z, 2a–d having aminoquinazoline scaffold was designed and synthesized. Their in vitro antiproliferative activities against RT112 bladder cancer cell line and inhibitory activities against FGFR3 kinase were tested. Most compounds showed good antiproliferative activities against RT112 bladder cancer cell line, and arylurea compounds 1a–z were more potent than arylamide compounds 2a–d. Among them, eight compounds 1a, 1d–g, 1l, 1y, and 1z showed potent activities with GI50values below submicromolar range. Especially, arylurea compounds 1d and 1g possessing 2,3-dimethyl and 3,4-dimethyl moieties exhibited superior or similar antiproliferative activity (GI50?=?8.8?nM and 30.2?nM, respectively) to AZD4547 (GI50?=?29.2?nM) as a reference standard.
Novel Sulfonaminoquinoline Hepcidin Antagonists
-
Page/Page column 173, (2012/09/05)
The present invention relates to novel hepcidin antagonists, pharmaceutical compositions comprising them and the use thereof as medicaments for the use in the treatment of iron metabolism disorders, such as, in particular, iron deficiency diseases and anemias, in particular anemias in connection with chronic inflammatory diseases.
